Publication Name	World Journal of Clinical Oncology
Manuscript ID	53157
Country	United States

Received	2019-12-08 01:31
Peer-Review Started	2019-12-08 01:32
To Make the First Decision
Return for Revision	2020-01-05 18:24
Revised	2020-03-06 01:57
Second Decision	2020-03-12 15:24
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2020-03-12 23:03
Articles in Press	2020-03-12 23:03
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2020-04-17 17:10
Publish the Manuscript Online	2020-04-22 10:32

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Case Report
Article Title	Personalized chemotherapy in clear cell adenocarcinoma of the urethra: A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Lisa B E Shields and Arash Rezazadeh Kalebasty
ORCID	Author(s) ORCID Number Lisa B E Shields http://orcid.org/0000-0002-1526-4063 Arash Rezazadeh Kalebasty http://orcid.org/0000-0002-1526-4062
Funding Agency and Grant Number
Corresponding Author	Arash Rezazadeh Kalebasty, MD, Doctor, Doctor, Norton Cancer Institute, Norton Healthcare, 315 East Broadway, Louisville, KY 40202, United States. arez@uci.edu
Key Words	Oncology; Clear cell adenocarcinoma; Urethra; Chemotherapy; Personalized; Genetic testing
Core Tip	Specialized genetic testing determines the presence or absence of certain mutations which may predict whether a patient with cancer may benefit from a specific chemotherapy regimen. We report the first case of a patient with metastatic clear cell adenocarcinoma of the urethra who underwent personalized chemotherapy after testing for cancer gene alterations. The patient achieved complete response after 6 cycles of paclitaxel and bevacizumab by positron emission tomography scan. Our case highlights the safe and effective use of non-platinum-based chemotherapy in clear cell adenocarcinoma of the urethra.
Publish Date	2020-04-22 10:32
Citation	Shields LBE, Kalebasty AR. Personalized chemotherapy in clear cell adenocarcinoma of the urethra: A case report. World J Clin Oncol 2020; 11(4): 243-249
URL	https://www.wjgnet.com/2218-4333/full/v11/i4/243.htm
DOI	https://dx.doi.org/10.5306/wjco.v11.i4.243

Full Article (PDF)	WJCO-11-243.pdf
Full Article (Word)	WJCO-11-243.docx
CARE Checklist–2016	53157-CARE-Checklist–2016-revision.tiff
Manuscript File	53157-Review.doc
Answering Reviewers	53157-Answering reviewers.pdf
Audio Core Tip	53157-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	53157-Conflict-of-interest statement.pdf
Copyright License Agreement	53157-Copyright license agreement.pdf
Signed Informed Consent Form(s) or Document(s)	53157-Informed consent statement.pdf
Peer-review Report	53157-Peer-review(s).pdf
Scientific Misconduct Check	53157-Scientific misconduct check.pdf
Scientific Editor Work List	53157-Scientific editor work list.pdf
CrossCheck Report	53157-CrossCheck report.pdf